title: Dopamine versus norepinephrine in the treatment of shock.
abstract: OBJECTIVE
  Which vasopressor agent, norepinephrine or dopamine, is superior in the treatment of shock?
  
  
  METHODS
  De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89.
  
  
  OBJECTIVE
  The authors of this study set out to compare 28-day mortality in patients with shock who were treated with either dopamine or norepinephrine as initial vasopressor therapy. The authors' secondary outcome measures included mortality beyond 28 days and adverse events associated with each agent.
authors.affiliation: Division of Emergency Medicine, University of Calgary, Calgary, AB. ncoxford@hotmail.com
authors.forename: Reviewed
authors.initials: R
authors.lastname: Nathan Coxford
authors.forename: Eddy
authors.initials: E
authors.lastname: Lang
authors.forename: Shawn
authors.initials: S
authors.lastname: Dowling
mesh_terms: D000328:Adult; D004298:Dopamine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D009638:Norepinephrine / Q000009:adverse effects / Q000627:therapeutic use*; D012769:Shock / Q000188:drug therapy*; D012770:Shock, Cardiogenic / Q000188:drug therapy; D016019:Survival Analysis; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D004298:Dopamine; D009638:Norepinephrine